A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency

Inclusion Criteria: * Adults with GHD as defined in the consensus guidelines for the diagnosis and treatment of adults with GHD * Stable human growth hormone (hGH) replacement therapy for at least 3 months Exclusion Criteria: * Participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation * Active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix * Proliferative retinopathy judged by retina-photo within the last year - only with concomitant diabetes * Heart insufficiency, New York Heart Association (NYHA) class above 2 * Adults with GHD with poorly controlled diabetes mellitus with a glycosylated haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment * Stable pituitary replacement therapy for less than 3 months